success rate of humira vs remicade for ulcerative colitis
- User
success rate of humira vs remicade for ulcerative colitis
- Assistant
The effectiveness of Humira (adalimumab) and Remicade (infliximab) can vary greatly from person to person, and it's important to note that what works best will depend on the individual's specific condition and overall health.
According to a 2017 study published in the Journal of Crohn's and Colitis, both drugs showed similar efficacy in inducing remission in moderate-to-severe ulcerative colitis. The study found that at week 8, roughly 18.5% of patients on Humira and 16.5% of patients on Remicade had achieved remission.
Another study published in 2014 in the American Journal of Gastroenterology showed that 22% of patients on Humira and 23% of patients on Remicade achieved remission by week 8.
However, a meta-analysis published in 2015 in the Annals of Internal Medicine found that Remicade was more effective than Humira in achieving remission in patients with ulcerative colitis, but the difference was not statistically significant.
Remember to consult with a healthcare professional for the most accurate information. They can provide guidance based on a comprehensive understanding of your personal medical history.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.